While the Impact-R™ is registered as a research tool and thus does not require FDA approval for marketing, the Impact™ system is expected to be cleared for marketing in the USA during the year 2010.

The intended uses of the device will be for anti-platelet therapy monitoring and screening of platelet dysfunctions disorders. The Impact™ system has an application mode for selective monitoring of anti-platelet drugs, allowing individual dose adjustment and drug selection. Its features (rapid, physiological, simple, cost effective) will help in designing a more rational approach to cardiovascular therapeutics, improving clinical outcome. After receipt of the FDA approval for marketing and the launch of the Impact™ in the USA market, the Company expects that its unique device will generate great interest in the cardiovascular market.